Uncategorised

Accomplishments

by |Published
Image is not available
Image is not available

Identifying potential therapies

Identifying potential therapies

Identifying potential therapies

Partnering with industry

Partnering with industry

Partnering with industry

Image is not available

Facilitating investment decisions

Facilitating investment decisions

Facilitating investment decisions

Image is not available

Publishing novel data

Publishing novel data

Publishing novel data

Image is not available

Supporting small biotech companies

Supporting small biotech companies

Supporting small biotech companies

Image is not available

Expanding capacity

Expanding capacity

Expanding capacity

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Drug candidates
Quilizumab & Mepolizumab
Anti-TSLP Treatment
CIC identified effective new molecule candidates for future investment, including ligelizumab (Novartis) for chronic spontaneous urticaria. Quilizumab (Genentech) and tezepelumab (Amgen) moved into phase II testing.
CIC has pursued other novel approaches, including antisense oligonucleotides, small molecule inhibitors, steroid receptor agonist, monoclonal antibodies. Study endpoints include safety, efficacy and assessments of on-target activity. Click here for a list of examples.
CIC tested a new anti-TSLP treatment for allergic asthma: tezepelumab. The study, published in NEJM, demonstrated significant anti-inflammatory effects in airways and circulation, captured media attention, and set the stage for rapid clinical development for asthma. Tezepelumab then moved into phase IIb testing.
Other novel molecules

Identifying potential therapies

Identifying potential therapies

Identifying potential therapies

Image is not available

Therapies

Partners

Investment decisions

Publications

Biotech support

Home

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Partnerships
New Therapies
CIC has partnered with 17 companies, including: AIM Therapeutics, Alexion Pharmaceuticals, Altair Pharmaceuticals, Amgen, Asmacure, AstraZeneca, Axikin Pharmaceuticals, Boehringer Ingelheim, Genentech, IVAX, MedImmune, Novartis, ONO Pharmaceutical, Schering-Plough, Topigen Pharmaceuticals, and Wyeth.
CIC partnered with Genentech to evaluate three compounds between 2007-2012. Findings were published in Clinical and Experimental Allergy and Science Translational Medicine, and one compound advanced to a Phase IIb trial.
CIC partnered with Amgen to identify one of the most exciting new therapies to date (tezepelumab), with findings published in NEJM. The high impact of these data was dependent on the study design, constructed within CIC expertise, and on the variety of outcomes that CIC sites can implement.
Evaluating Compounds

Partnering with industry

Partnering with industry

Partnering with industry

Image is not available

Therapies

Therapies

Therapies

Therapies

Therapies

Partners

Partners

Investment decisions

Investment decisions

Publications

Publications

Biotech support

Home

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Discovery Investments
CIC trials have allowed companies to prioritize their discovery investments with small, effective studies, and validated models that are 100% accurate for making “no-go” decisions.

Facilitating investment decisions

Facilitating investment decisions

Facilitating investment decisions

Image is not available

Therapies

Partners

Investment decisions

Publications

Biotech support

Home

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Over 80 refereed publications
CIC has produced over 80 refereed publications sharing novel data on efficacy and mechanism of action, including in high-impact scientific journals such as:

Publishing novel data

Publishing novel data

Publishing novel data

Image is not available
New England Journal of Medicine, Science Translational Medicine, The Lancet, American Journal of Respiratory and Critical Care Medicine, and The Journal of Allergy and Clinical Immunology

Therapies

Partners

Investment decisions

Publications

Biotech support

Home

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Topigen Pharmaceuticals
CIC facilitated the success of Canadian start-up biotechnology company, Topigen Pharmaceuticals, by demonstrating the efficacy and target knock-down by the drug ASM08, resulting in Topigen's acquisition by Pharmaxis.

Supporting small biotech companies

Supporting small biotech companies

Supporting small biotech companies

Image is not available
Commercialization insights
CIC provided new Canadian biotechnology companies (Asmacure, AIM Therapeutics) with business and commercialization insights on which they based strategic investment decisions.

Therapies

Partners

Investment decisions

Publications

Biotech support

Home

Slider

CIC's accomplishments: from identifying new therapies to publishing novel data.

You may also like

Published

Study methods

BRONCHOPROVOCATION Inhaled allergen (PC20/PD20, early & late asthmatic responses) Methacholine airway hyperresponsiveness Inhaled mannitol (Aridol®) Exercise-induced bronchoconstriction Hypertonic saline Capsaicin cough challenge […]

Published

Staff

Across the Collaborative and within each study site, CIC employs the expertise of all the highly-trained research, technical and clinical staff required […]

WordPress Image Lightbox